https://ipharmag.com/article/outer-bio-polansky-skin-biotech-launch iPharmag en 2026-08-28T03:04:07+00:00 A New Skin Biotech Keeps Human Tissue Alive for a Month to Hunt Better Ingredients https://ipharmag.com/article/myotis-bat-genomes-longevity-cancer-virus iPharmag en 2026-08-28T03:04:07+00:00 Bat Genomes Reveal How These Animals Resist Viruses and Cancer — and Live So Long https://ipharmag.com/article/lisraya-brepocitinib-fda-first-oral-dermatomyositis iPharmag en 2026-08-28T03:04:07+00:00 FDA Approves Lisraya, the First Oral Targeted Therapy for Dermatomyositis https://ipharmag.com/article/early-life-sugar-rationing-70-year-health-cancer iPharmag en 2026-08-28T03:04:07+00:00 Less Sugar in the First 1,000 Days Was Linked to Better Health 70 Years Later https://ipharmag.com/article/astrazeneca-amgen-tezspire-eosinophilic-esophagitis iPharmag en 2026-08-28T03:04:07+00:00 AstraZeneca and Amgen’s Tezspire Hits in Esophagus Disease, Eyeing Dupixent’s Turf https://ipharmag.com/article/zika-vaccine-t-cell-approach-mice-la-jolla iPharmag en 2026-08-27T15:37:06+00:00 A New Zika Vaccine Strategy Protects Through T Cells — Sidestepping a Dangerous Antibody Trap https://ipharmag.com/article/smart-nanoparticles-glioblastoma-surgery-imaging-destroy iPharmag en 2026-08-27T15:37:06+00:00 Smart Nanoparticles Make Brain Tumors Glow — Then Attack What Surgery Leaves Behind https://ipharmag.com/article/rasonque-daraxonrasib-fda-approval-pancreatic-cancer-ras iPharmag en 2026-08-27T15:37:06+00:00 FDA Approves First RAS-Targeted Drug for Pancreatic Cancer, Nearly Doubling Survival in Trial https://ipharmag.com/article/jnj-imaavy-nipocalimab-waiha-first-fda-approval iPharmag en 2026-08-27T15:37:06+00:00 J&J’s Imaavy Becomes the First Approved Treatment for a Rare Autoimmune Anemia https://ipharmag.com/article/biohaven-sk-biopharm-opakalim-795m-epilepsy-deal iPharmag en 2026-08-27T15:37:06+00:00 Cash-Strapped Biohaven Sells Its Lead Epilepsy Drug to SK for Up to $795M